PriceTargets.com logo

Adaptimmune Therapeutics - ADAP Stock Price Target and Predictions

  • Consensus Rating: Reduce
  • Consensus Price Target: $1.35
  • Forecasted Upside: 2,234.48%
  • Number of Analysts: 8
  • Breakdown:
  • 2 Sell Ratings
  • 5 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$0.06 As of 10/27/2025 08:59 PM ET
▼ -0.0068 (-10.51%)

This chart shows the closing price for ADAP by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Adaptimmune Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ADAP and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ADAP

Analyst Price Target is $1.35
▲ +2,234.48% Upside Potential
This price target is based on 8 analysts offering 12 month price targets for Adaptimmune Therapeutics in the last 3 months. The average price target is $1.35, with a high forecast of $3.00 and a low forecast of $0.46. The average price target represents a 2,234.48% upside from the last price of $0.06.

This chart shows the closing price for ADAP for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Reduce

The current consensus among 8 polled investment analysts is to reduce stock in Adaptimmune Therapeutics. This rating has held steady since September 2025, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
6/12/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/10/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/9/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/9/2025
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 1 sell ratings
Ratings as of
6/7/2025
  • 0 strong buy ratings
  • 1 buy ratings
  • 5 hold ratings
  • 1 sell ratings
Ratings as of
9/5/2025
  • 0 strong buy ratings
  • 1 buy ratings
  • 5 hold ratings
  • 2 sell ratings
Ratings as of
11/4/2025
  • 0 strong buy ratings
  • 1 buy ratings
  • 5 hold ratings
  • 2 sell ratings
Ratings as of
12/4/2025

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 5 hold ratings
  • 2 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
10/8/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
9/27/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
7/29/2025GuggenheimDowngradeStrong-Buy ➝ Hold
7/29/2025HC WainwrightReiterated RatingBuy ➝ Neutral
6/26/2025MizuhoDowngradeOutperform ➝ Neutral$1.50 ➝ $0.50
5/14/2025Wells Fargo & CompanyLower TargetEqual Weight ➝ Equal Weight$1.50 ➝ $1.00
5/14/2025BarclaysLower TargetUnderweight ➝ Underweight$1.00 ➝ $0.46
4/11/2025Jones TradingDowngradeStrong-Buy ➝ Hold
4/1/2025HC WainwrightLower TargetBuy ➝ Buy$3.50 ➝ $3.00
3/26/2025GuggenheimLower TargetBuy ➝ Buy$3.00 ➝ $1.75
3/21/2025Wells Fargo & CompanyLower TargetEqual Weight ➝ Equal Weight$2.00 ➝ $1.50
3/21/2025ScotiabankLower TargetSector Outperform ➝ Sector Outperform$3.15 ➝ $1.40
11/27/2024MizuhoLower TargetOutperform ➝ Outperform$3.00 ➝ $1.50
11/15/2024GuggenheimLower TargetBuy ➝ Buy$4.00 ➝ $3.00
11/14/2024HC WainwrightLower TargetBuy ➝ Buy$4.00 ➝ $3.50
8/13/2024HC WainwrightReiterated RatingBuy ➝ Buy$4.00 ➝ $4.00
8/5/2024HC WainwrightReiterated RatingBuy ➝ Buy$4.00 ➝ $4.00
7/30/2024HC WainwrightInitiated CoverageBuy$4.00
5/30/2024ScotiabankInitiated CoverageSector Outperform$3.15
5/17/2024MizuhoLower TargetBuy ➝ Buy$9.00 ➝ $3.00
8/10/2023GuggenheimLower Target$5.00 ➝ $4.00
8/10/2023BarclaysLower TargetUnderweight ➝ Underweight$2.00 ➝ $1.00
4/17/2023EF Hutton Acquisition Co. IReiterated RatingBuy$10.00
4/11/2023EF Hutton Acquisition Co. IReiterated RatingBuy$10.00
3/24/2023Bryan, Garnier & CoInitiated CoverageBuy$3.60
3/6/2023EF Hutton Acquisition Co. IReiterated RatingBuy$10.00
1/5/2023EF Hutton Acquisition Co. IInitiated CoverageBuy$10.00
1/3/2023GuggenheimUpgradeNeutral ➝ Buy$5.00
11/14/2022Wells Fargo & CompanyBoost TargetEqual Weight$1.50 ➝ $3.00
11/9/2022MizuhoUpgradeNeutral ➝ Buy$9.00
10/4/2022Wells Fargo & CompanyLower TargetEqual Weight$7.00 ➝ $1.50
3/15/2022Leerink PartnersLower TargetMarket Perform$7.00 ➝ $3.00
11/9/2021Leerink PartnersReiterated RatingHold$7.00
9/22/2021Wells Fargo & CompanyBoost TargetEqual Weight$6.00 ➝ $7.00
9/13/2021JonestradingReiterated RatingBuy$15.00
9/13/2021Leerink PartnersBoost TargetMarket Perform$6.00 ➝ $7.00
9/9/2021MizuhoInitiated CoverageHold$9.00
9/7/2021Leerink PartnersBoost TargetMarket Perform$5.00 ➝ $6.00
9/7/2021JonestradingReiterated RatingBuy$15.00
8/10/2021Leerink PartnersLower TargetMarket Perform$6.00 ➝ $5.00
5/28/2021BarclaysInitiated CoverageUnderweight$4.00
5/23/2021Leerink PartnersReiterated RatingHold
(Data available from 12/4/2020 forward)

News Sentiment Rating

0.00 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 4 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/8/2025
  • 7 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
6/7/2025
  • 1 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/7/2025
  • 1 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 2 very negative mentions
Mentions as of
8/6/2025
  • 1 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
9/5/2025
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/5/2025
  • 1 very positive mentions
  • 10 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/4/2025
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/4/2025

Current Sentiment

  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
Adaptimmune Therapeutics logo
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers. The company has strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic and allogeneic T-cell therapies; research, collaboration, and license agreement with Universal Cells, Inc.; third-party collaborations with Noile-Immune and Alpine Immune Sciences; and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.
Read More

Today's Range

Now: $0.06
Low: $0.05
High: $0.07

50 Day Range

MA: $0.09
Low: $0.05
High: $0.22

52 Week Range

Now: $0.06
Low: $0.04
High: $0.86

Volume

49,262,772 shs

Average Volume

127,153,136 shs

Market Capitalization

$15.35 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.49

Frequently Asked Questions

What sell-side analysts currently cover shares of Adaptimmune Therapeutics?

The following sell-side analysts have issued reports on Adaptimmune Therapeutics in the last twelve months: Barclays PLC, Guggenheim, HC Wainwright, Jones Trading, Mizuho, Scotiabank, Wall Street Zen, Weiss Ratings, and Wells Fargo & Company.
View the latest analyst ratings for ADAP.

What is the current price target for Adaptimmune Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Adaptimmune Therapeutics in the last year. Their average twelve-month price target is $1.35, suggesting a possible upside of 2,234.5%. HC Wainwright has the highest price target set, predicting ADAP will reach $3.00 in the next twelve months. Barclays PLC has the lowest price target set, forecasting a price of $0.46 for Adaptimmune Therapeutics in the next year.
View the latest price targets for ADAP.

What is the current consensus analyst rating for Adaptimmune Therapeutics?

Adaptimmune Therapeutics currently has 2 sell ratings, 5 hold ratings and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Reduce."
View the latest ratings for ADAP.

What other companies compete with Adaptimmune Therapeutics?

Other companies that are similar to Adaptimmune Therapeutics include Aligos Therapeutics, Adlai Nortye, Senti Biosciences, Aadi Bioscience and Talphera. Learn More about companies similar to Adaptimmune Therapeutics.

How do I contact Adaptimmune Therapeutics' investor relations team?

Adaptimmune Therapeutics' physical mailing address is 60 JUBILEE AVENUE MILTON PARK OXFORDSHIRE, ABINGDON X0, OX14 4RX. The biotechnology company's listed phone number is 441235430000 and its investor relations email address is [email protected]. The official website for Adaptimmune Therapeutics is www.adaptimmune.com. Learn More about contacing Adaptimmune Therapeutics investor relations.